Additionally, a phase 1/2 study evaluated tegavivint, a TBL1 inhibitor, in advanced HCC patients with beta-catenin activating mutations, aiming to characterize the safety, pharmacokinetics/pharmacodynamics (PK/PD), and preliminary antitumor activity of tegavivint, offering a novel targeted approach for HCC with specific genetic profiles (21). This evidence concerns the gene CTNNB1 and hepatocellular carcinoma.